In this GEN webinar, experts from AbbVie and Benchling will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma.
In this GEN webinar, Dr. Helen Cooper, a leading analytic alchemist from the University of Birmingham, U.K., will discuss improvements in mass spectrometry imaging technology that enable the characterization of the precise protein forms present in multiprotein complexes.
In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product characterization in GMP release and stability studies of novel cell and gene therapies.
In this GEN webinar, we will aim to unlock the secrets behind the iterative process development that ensures the highest standards of mRNA manufacturing.
In this GEN webinar, Andrea O’Hara, PhD, a multiomics expert at GENEWIZ from Azenta Life Sciences, will discuss how to use nanopore sequencing technology to enhance the precision and efficiency of cell and gene therapy programs.
In this GEN webinar, experts from Xilis and University of Washington and Plurexa will share results from recent research using patient-derived organoids to study multiple myeloma and polycystic kidney disease.
In this GEN webinar, Mark Stockdale will discuss how the application of synthetic biology and artificial intelligence can be used to improve the safety, potency and manufacturability of gene therapies, and introduce AAV Edge, a comprehensive platform for end-to-end gene therapy optimization—from payload design to production cell lines and model-guided processes.
On this GEN webinar, experts from Regeneron Pharmaceuticals, Song Nie, PhD, and Tim Tiambeng, PhD, will discuss two novel methods for characterizing AAV-based gene therapy products.
In this GEN webinar, Jeremy Tomlinson, PhD, will discuss the pathogenesis of MASLD, share examples from recent research that highlight current progress and advancements in the clinic, and explore the importance of developing efficient pre-clinical models to identify and characterize novel cellular targets associated with disease progression.
In this GEN webinar, Shyra Gardai, PhD, will demonstrate the potential of the novel extracellular degrading platform, EpiTACs, using the development of bispecific antibodies to degrade the canonical receptor tyrosine kinase epidermal growth factor receptor as a case study
In this GEN webinar, Ravi Goel Lal from the Arnold lab at Caltech will present the basics and applications of Active Learning-assisted Directed Evolution (ALDE). He will be joined by Dr. Galit Meshulam-Simon, Associate Director of Commercial Applications at Elegen.
